← Company library
Korea / Company briefSources checked 2026-11-18

GeneMedicine

A company developing oncolytic adenovirus gene therapies built on patented genetic-engineering technology.

GM103

Stage unconfirmed

An oncolytic adenovirus that induces tumour-specific immune responses and inhibits tumour angiogenesis, being prepared for a Phase 1 trial in metastatic lung and liver cancer.

GM101 / GM102

Stage unconfirmed

Oncolytic adenovirus candidates the company showcased at a 2026 exhibition.

Official role guide

GeneMedicine careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. KOREA LIFE SCIENCE WEEK 2026 참가업체 진메디신 ↗KOREA LIFE SCIENCE WEEK · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  2. GM103 pipeline ↗GeneMedicine · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  3. 2026년도 제1차 국가신약개발사업 신규지원 대상과제 선정 공고 ↗국가신약개발사업단 · Published 2026-04-30 · Sources checked 2026-11-18 · Original unavailable